Kiley Juergens Wealth Management’s ResMed RMD Stock Holding History

Kiley Juergens Wealth Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-448	Closed	-$51K	–	502
2018 Q3	$51K	Buy	448 +1	+0.2%	+$110	0.04%	234
2018 Q2	$46K	Buy	+447	New	+$45.2K	0.04%	212
2018 Q1	–	Sell	-444	Closed	-$37K	–	486
2017 Q4	$37K	Buy	+444	New	+$36.7K	0.03%	242

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kiley Juergens Wealth Management's RMD Position: Q4 2018 in Review

Kiley Juergens Wealth Management sold out of ResMed (RMD) in Q4 2018, closing a stake of 448 shares — an estimated $51K sold.

Kiley Juergens Wealth Management first reported a position in RMD in Q4 2017 and held it in 3 quarters. The position peaked at $51K in Q3 2018. 501 funds tracked by Wall St. Rank hold RMD as of Q4 2018.

Kiley Juergens Wealth Management reported no remaining ResMed position as of Q4 2018 after selling out during the quarter.
Kiley Juergens Wealth Management sold 448 ResMed shares in Q4 2018, an estimated $51K.
Kiley Juergens Wealth Management first reported a position in ResMed in Q4 2017 and held it in 3 quarters.
Kiley Juergens Wealth Management's ResMed position peaked at $51K in Q3 2018.
501 funds tracked by Wall St. Rank held ResMed as of Q4 2018.

Based on Kiley Juergens Wealth Management's 13F filing for Q4 2018, filed 15 Jan 2019.